Orexo AB ( (ORXOF) ) has released its Q1 earnings. Here is a breakdown of the information Orexo AB presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Orexo AB is a commercial-stage pharmaceutical company specializing in developing drugs using advanced drug delivery technologies, with a focus on addressing opioid dependence in the US market. In its Q1 2025 earnings report, Orexo reported total net revenues of SEK 146.2 million, a slight increase from the previous year, with a positive cash flow from operating activities. However, the company faced a decrease in EBITDA and net earnings, reflecting challenges in the volatile market environment. Key highlights include stable US commercial operations, positive clinical data for their OX640 nasal epinephrine product, and strategic advancements in their AmorphOX technology. Looking ahead, Orexo aims for a positive EBITDA for the full year 2025, with expectations of improved financial performance as market conditions stabilize and development projects progress.